Skip to main content
Figure 1 | Annals of Surgical Innovation and Research

Figure 1

From: Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding

Figure 1

Kaplan-Meier estimates for the probability of bleeding after treatment with different concentrations of rThrombin or placebo. TTH was measured in the rabbit AV shunt model of anastomotic bleeding after treatment with heparin + clopidogrel. PTFE graft segments were punctured, and AGS containing a standardized volume of 1000 IU/mL or 125 IU/mL rThrombin or placebo was applied to the bleeding surface. The TTH observation period extended from 60 seconds to 300 seconds. 1000 IU/mL rThrombin: N = 14 grafts. 125 IU/mL rThrombin: N = 14 grafts. Placebo: N = 10 grafts.

Back to article page

Annals of Surgical Innovation and Research

ISSN: 1750-1164

Contact us